Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 1999

View Archived Issues

rhIL-11 tested in active Crohn's disease

Pharmacological characteristics of PK inhibitor CGP-41251 explored

Cypros receives additional notice of allowance concerning U.S. patent on Cordox

Teva's tender offer to acquire Copley expires

Seragen sublicenses daclizumab patents to Roche

Genzyme Molecular Oncology announces initiation of breast cancer vaccine trial

UroCor and Mallinckrodt enter marketing agreement for brachytherapy implants

M-Vax nearing commercialization in several markets

BASF's new ET antagonists described in patent literature

Warner-Lambert discloses new IL-8 (CXCR1/CXCR2) receptor antagonists

Novel biaryl compounds for herpesvirus infections identified by Tularik researchers

Benzimidazole COX-2 inhibitors in development at Pfizer

Human factor Xa inhibitors under evaluation at Roche Diagnostics

Solvay scientists describe new motilin agonists derived from erythromycin

Faes researches piperazine-based atypical antipsychotics

BBI Biotech receives three SBIR grants

Potential new use of nefiracetam profiled at 23rd IEC meeting

Boehringer Ingelheim's TNF-alpha-1a launched in Europe for soft tissue sarcoma

Sacricin characterized as potential novel antiepileptic in preclinical and early clinical studies

German company obtains renal cell carcinoma MAb license from Centocor

AstraZeneca and Knoll establish marketing agreement for Reductil

Novel bifunctional compound BN-80933 provides remarkable neuroprotection in several tests

DuPont seeks European approval for ultrasound contrast agent

K(ATP) channel opener with improved cardioprotective efficacy designed at BMS

New transdermal drug delivery system receives U.S. patent coverage

Sonata clears final regulatory step for marketing in the U.S.